Results 211 to 220 of about 222,217 (297)

Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition

Allergy, EarlyView.
This study aimed to assess diagnostic delay among patients with eosinophilic granulomatosis with polyangiitis (EGPA) and identify clinical characteristics associated with delayed recognition. EGPA diagnosis was delayed by nearly five years from symptom onset in this single‐center cohort.
Vani Mulkareddy, Kalena Liu, Shreya Mandloi, Kelsey Limage, Samuel R. Shing, Gurston G. Nyquist, Jessica Most, David Kennedy, Elina Toskala, Damaris Pena‐Evertz   +9 more
wiley   +1 more source

Primary Diffuse Large B-Cell Lymphoma of the Female Genital Tract: A Rare Case Presentation With Literature Review. [PDF]

Case Rep Hematol
Xu F, Lee JLJ, Yi B, Chen W.
europepmc   +1 more source

Radiation therapy for persistent or progressive mediastinal lymphoma after chemotherapy in FeLV‐positive cats: a retrospective case series of four cats

Australian Veterinary Journal, EarlyView.
Background Mediastinal lymphoma in feline leukaemia virus (FeLV)‐positive cats is associated with a poor prognosis, and therapeutic options may be limited when adequate disease control is not achieved with chemotherapy. The efficacy of radiation therapy in this setting has not been established.
A Uno, T Hasegawa, T Mori
wiley   +1 more source

Functional brain network alterations linked to cancer-related cognitive impairment in breast cancer patients. [PDF]

Oncologist
Benelli A, Reilly J, Ortega-Márquez J, Parsons M, Dietrich J, Sprugnoli G, Fregni F, Santarnecchi E.   +7 more
europepmc   +1 more source

Prognostic impact of blood Epstein–Barr virus‐DNA in patients with peripheral T‐cell lymphoma, not otherwise specified

British Journal of Haematology, EarlyView.
Summary Peripheral T‐cell lymphoma, not otherwise specified (PTCL‐NOS), is a heterogeneous nodal T‐ and natural killer (NK)‐cell lymphoma with limited prognostic biomarkers. A subset of PTCL‐NOS characterized by Epstein–Barr virus (EBV) involvement in tumour cells has recently been recognized as EBV‐positive nodal T‐ and NK‐cell lymphoma (EBV+ nPTCL ...
Hyunseok Yoon, Hyungwoo Cho, In Hye Song, Sejin Kim, So Heun Lee, Kyoungmin Lee, Shin Kim, Chan‐Sik Park, Eun Jin Chae, Kyung Won Kim, Jin‐Sook Ryu, Sang‐Wook Lee, Jaewon Hyung, Heounjeong Go, Dok Hyun Yoon   +14 more
wiley   +1 more source

BrECADD in three days: Implementation of a condensed intensive first‐line regimen in Hodgkin lymphoma

British Journal of Haematology, EarlyView.
BrECADD can be delivered over 3 days instead of four, reducing intravenous treatment days by 25% without compromising dose intensity. Among 30 patients with advanced‐stage Hodgkin lymphoma, no unexpected toxicity was observed; there were no early discontinuations, and 1‐year progression‐free and overall survival were both 100%.
Christian Peter Jaworek, Maja Supprian, Paul Jan Bröckelmann, Hishan Tharmaseelan, Justin Ferdinandus, Dennis A. Eichenauer, Anne Sophie Robertz, Janina Jablonski, Vincent Combüchen, Jan‐Oliver Staak, Karin Töpelt, Jan‐Michel Heger, Jon Rischewski, Jannik Stemler, Wolfram Klapper, Peter Borchmann, Bastian von Tresckow   +16 more
wiley   +1 more source

Spirulina platensis and β-glucan mitigate cyclophosphamide-induced Immunosuppression in broilers: Differential effects of preventive and therapeutic strategies via redox-inflammatory modulation. [PDF]

Poult Sci
Elshaitany KAM, Mokhbatly AA, Ghazy EW, ELazab MFA, Shukry M, Assar DH.   +5 more
europepmc   +1 more source

Real‐world outcomes of ide‐cel and cilta‐cel in relapsed/refractory multiple myeloma: A nationwide, retrospective analysis in Austria

British Journal of Haematology, EarlyView.
Summary B‐cell maturation antigen‐directed chimeric antigen receptor (CAR) T cells have revolutionized the treatment of relapsed/refractory multiple myeloma. However, no randomized head‐to‐head comparison of idecabtagene vicleucel (ide‐cel) and ciltacabtagene autoleucel (cilta‐cel) is available, and real‐world data suggest differences in efficacy and ...
Irene Strassl, Alexander Nikoloudis, Lina Zoe Ruesing, Thomas Melchardt, Michael Leisch, Eduard Schulz, Annkristin Heine, Peter Neumeister, Normann Steiner, Dominik Wolf, Wolfgang Willenbacher, Petra Pichler‐Izmir, Theresa Lentner, Johannes Clausen, Veronika Buxhofer‐Ausch, Sigrid Machherndl‐Spandl, Olga Saini, Dagmar Wipplinger, Holger Rumpold, Nina Worel, Werner Rabitsch, Axel Schulenburg, Hermine Agis, Maria‐Theresa Krauth   +23 more
wiley   +1 more source

Nb₂C-based MXenes for controlled cyclophosphamide delivery: role of surface functionalization and sulfur doping. [PDF]

RSC Adv
Govindan M, Petchimuthu R, Baskaran A, Sivasankar Kumar J, Rajalakshmi Mohanraj H, Kala Christian P, Kombiah I, Yoshiyuki K.   +7 more
europepmc   +1 more source

SENIOR‐IPI: An easily applicable prognostic index for first‐line large B‐cell lymphomas patients >80 years treated with curative intent

British Journal of Haematology, EarlyView.
Summary Using LYmphoma Study Association clinical trials combining 438 first‐line large B‐cell lymphomas (LBCL) patients >80 years old, we defined SENIOR‐IPI, an easily applicable prognostic index for this elderly population treated with an anti‐CD20‐miniCHOP (cyclophosphamide, doxorubicin, vincristine and prednisone)‐based regimen.
Sydney Dubois, Fanny Cherblanc, Aurelien Belot, Lucie Oberic, Hervé Ghesquières, Corinne Haioun, Hervé Tilly, Jean‐Philippe Jais, Fabrice Jardin   +8 more
wiley   +1 more source